Adult-onset growth hormone deficiency - Epidemiology Forecast - 2032

January 2022 | 60 pages | ID: AADFC65930BEEN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Adult-onset growth hormone deficiency - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Adult-onset growth hormone deficiency epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Adult-onset growth hormone deficiency Understanding

The DelveInsight Adult-onset growth hormone deficiency epidemiology report gives a thorough understanding of the Adult-onset growth hormone deficiency by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Adult-onset growth hormone deficiency in the US, Europe, and Japan. The report covers the detailed information of the Adult-onset growth hormone deficiency epidemiology scenario in seven major countries (US, EU5, and Japan).

Adult-onset growth hormone deficiency Epidemiology Perspective by DelveInsight

The Adult-onset growth hormone deficiency epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Adult-onset growth hormone deficiency epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Adult-onset growth hormone deficiency epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Adult-onset growth hormone deficiency Detailed Epidemiology Segmentation

The Adult-onset growth hormone deficiency epidemiology covered in the report provides historical as well as forecasted Adult-onset growth hormone deficiency epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Adult-onset growth hormone deficiency report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Adult-onset growth hormone deficiency report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Adult-onset growth hormone deficiency Epidemiology Report and Model provide an overview of the global trends of Adult-onset growth hormone deficiency in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Adult-onset growth hormone deficiency in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Adult-onset growth hormone deficiency
• The report provides the segmentation of the Adult-onset growth hormone deficiency epidemiology

Report Highlights

• 11-year Forecast of Adult-onset growth hormone deficiency epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Adult-onset growth hormone deficiency
• Cases of Adult-onset growth hormone deficiency by Mutation Types
• Adult-onset growth hormone deficiency Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Adult-onset growth hormone deficiency?
• What are the key findings pertaining to the Adult-onset growth hormone deficiency epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Adult-onset growth hormone deficiency across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Adult-onset growth hormone deficiency?
• What are the currently available treatments of Adult-onset growth hormone deficiency?

Reasons to buy

The Adult-onset growth hormone deficiency Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Adult-onset growth hormone deficiency market
• Quantify patient populations in the global Adult-onset growth hormone deficiency market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Adult-onset growth hormone deficiency therapeutics in each of the markets covered
• Understand the magnitude of Adult-onset growth hormone deficiency population by its epidemiology
• The Adult-onset growth hormone deficiency Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF ADULT-ONSET GROWTH HORMONE DEFICIENCY

3. ADULT-ONSET GROWTH HORMONE DEFICIENCY: DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Adult-onset growth hormone deficiency Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Adult-onset growth hormone deficiency Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Adult-onset growth hormone deficiency Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Adult-onset growth hormone deficiency Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Adult-onset growth hormone deficiency Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Adult-onset growth hormone deficiency Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Adult-onset growth hormone deficiency Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Adult-onset growth hormone deficiency Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Adult-onset growth hormone deficiency Treatment and Management
6.2. Adult-onset growth hormone deficiency Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Adult-onset growth hormone deficiency Epidemiology in 7MM (2019-2032)
Table 2: Adult-onset growth hormone deficiency Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Adult-onset growth hormone deficiency Epidemiology in the United States (2019-2032)
Table 4: Adult-onset growth hormone deficiency Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Adult-onset growth hormone deficiency Epidemiology in Germany (2019-2032)
Table 6: Adult-onset growth hormone deficiency Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Adult-onset growth hormone deficiency Epidemiology in France (2019-2032)
Table 8: Adult-onset growth hormone deficiency Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Adult-onset growth hormone deficiency Epidemiology in Italy (2019-2032)
Table 10: Adult-onset growth hormone deficiency Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Adult-onset growth hormone deficiency Epidemiology in Spain (2019-2032)
Table 12: Adult-onset growth hormone deficiency Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Adult-onset growth hormone deficiency Epidemiology in the United Kingdom (2019-2032)
Table 14: Adult-onset growth hormone deficiency Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Adult-onset growth hormone deficiency Epidemiology in Japan (2019-2032)
Table 16: Adult-onset growth hormone deficiency Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Adult-onset growth hormone deficiency Epidemiology in 7MM (2019-2032)
Figure 2 Adult-onset growth hormone deficiency Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Adult-onset growth hormone deficiency Epidemiology in the United States (2019-2032)
Figure 4 Adult-onset growth hormone deficiency Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Adult-onset growth hormone deficiency Epidemiology in Germany (2019-2032)
Figure 6 Adult-onset growth hormone deficiency Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Adult-onset growth hormone deficiency Epidemiology in France (2019-2032)
Figure 8 Adult-onset growth hormone deficiency Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Adult-onset growth hormone deficiency Epidemiology in Italy (2019-2032)
Figure 10 Adult-onset growth hormone deficiency Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Adult-onset growth hormone deficiency Epidemiology in Spain (2019-2032)
Figure 12 Adult-onset growth hormone deficiency Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Adult-onset growth hormone deficiency Epidemiology in the United Kingdom (2019-2032)
Figure 14 Adult-onset growth hormone deficiency Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Adult-onset growth hormone deficiency Epidemiology in Japan (2019-2032)
Figure 16 Adult-onset growth hormone deficiency Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report